Literature DB >> 29055982

Vitamin A status and its determinants in patients with cystic fibrosis.

Ewa Sapiejka1, Patrycja Krzyżanowska2, Dariusz Walkowiak3, Ewa Wenska-Chyży2, Mariusz Szczepanik2, Szczepan Cofta4, Andrzej Pogorzelski5, Wojciech Skorupa6, Jarosław Walkowiak2.   

Abstract

BACKGROUND: Routine administration of vitamin A, recommended in CF patients, can help to prevent its deficiency. However, high vitamin A supplementation may lead to its excessive level and possible toxicity. Therefore, the aim of the present study was to assess the status of vitamin A and the determinants of its body resources in CF patients.
METHODS: In 196 CF patients aged from 4 months to 47 years, the following parameters  were analysed: nutritional status (standardized body weight and height, serum albumin concentration) and clinical expression of disease (lung function - spirometry; biochemical markers of liver function - ALT, AST, GGT; respiratory tract colonization by Pseudomonas aeruginosa; diabetes; cirrhosis, non-cirrhotic liver disease; exocrine pancreatic function - fecal elastase-1 concentration; blood clotting -  INR  and  vitamin  A supplementation).
RESULTS: Median vitamin A concentration in the study group was 383.0 ng/ml (1st-3rd quartile: 316.5-457.0). Vitamin A deficiency was found in 32 (16.3%) subjects studied. Vitamin A concentrations above the reference range were observed only in 3 (1.5%) CF patients. CF patients with vitamin A deficiency were significantly older and had lower values of FEV1 compared to CF subjects with normal vitamin A status. Moreover, vitamin A deficiency occurred more frequently in CF patients with diabetes, Pseudomonas aeruginosa colo- nization, worse lung function and in those without vitamin A supplementation. However, in multiple linear regression analyses, none of the independent variables was documented to be important for predicting vita- min A status.
CONCLUSIONS: Vitamin A body resources in CF patients are mostly normal. Moreover, there are no good de- terminants of vitamin A status in these patients. Further studies targeted at exploring potential toxicity and deficiencies of vitamin A in CF patients are needed.

Entities:  

Keywords:  fat-soluble vitamins; high-performance liquid chromatography; liver cirrhosis; pancreatic disease; retinol

Mesh:

Substances:

Year:  2017        PMID: 29055982     DOI: 10.17306/J.AFS.0473

Source DB:  PubMed          Journal:  Acta Sci Pol Technol Aliment        ISSN: 1644-0730


  3 in total

1.  Molecular Heterogeneity in Cystic Fibrosis.

Authors:  Hasret A Civan; Serhat Seyhan
Journal:  J Pediatr Genet       Date:  2020-02-17

2.  Fat-Soluble Vitamin Supplementation Using Liposomes, Cyclodextrins, or Medium-Chain Triglycerides in Cystic Fibrosis: A Randomized Controlled Trial.

Authors:  Jan K Nowak; Paulina Sobkowiak; Sławomira Drzymała-Czyż; Patrycja Krzyżanowska-Jankowska; Ewa Sapiejka; Wojciech Skorupa; Andrzej Pogorzelski; Agata Nowicka; Irena Wojsyk-Banaszak; Szymon Kurek; Barbara Zielińska-Psuja; Aleksandra Lisowska; Jarosław Walkowiak
Journal:  Nutrients       Date:  2021-12-20       Impact factor: 5.717

3.  Fat-Soluble Vitamins in Standard vs. Liposomal Form Enriched with Vitamin K2 in Cystic Fibrosis: A Randomized Multi-Center Trial.

Authors:  Jan Krzysztof Nowak; Patrycja Krzyżanowska-Jankowska; Sławomira Drzymała-Czyż; Joanna Goździk-Spychalska; Irena Wojsyk-Banaszak; Wojciech Skorupa; Ewa Sapiejka; Anna Miśkiewicz-Chotnicka; Jan Brylak; Barbara Zielińska-Psuja; Aleksandra Lisowska; Jarosław Walkowiak
Journal:  J Clin Med       Date:  2022-01-17       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.